KR100441638B1 - 새로운 에이사이클릭 뉴클레오사이드 포스포네이트유도체, 그의 염 및 합성 방법 - Google Patents

새로운 에이사이클릭 뉴클레오사이드 포스포네이트유도체, 그의 염 및 합성 방법 Download PDF

Info

Publication number
KR100441638B1
KR100441638B1 KR10-2002-0003051A KR20020003051A KR100441638B1 KR 100441638 B1 KR100441638 B1 KR 100441638B1 KR 20020003051 A KR20020003051 A KR 20020003051A KR 100441638 B1 KR100441638 B1 KR 100441638B1
Authority
KR
South Korea
Prior art keywords
methyl
compound
amino
oxy
purin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-2002-0003051A
Other languages
English (en)
Korean (ko)
Other versions
KR20020062216A (ko
Inventor
최종류
김정민
노기윤
조동규
임재홍
황재택
조우영
장현숙
이장호
김태균
조승주
김경원
최태생
김청미
김용주
Original Assignee
주식회사 엘지생명과학
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 엘지생명과학 filed Critical 주식회사 엘지생명과학
Publication of KR20020062216A publication Critical patent/KR20020062216A/ko
Application granted granted Critical
Publication of KR100441638B1 publication Critical patent/KR100441638B1/ko
Assigned to 주식회사 엘지화학 reassignment 주식회사 엘지화학 권리의 전부이전등록 Assignors: 주식회사 엘지생명과학
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR10-2002-0003051A 2001-01-19 2002-01-18 새로운 에이사이클릭 뉴클레오사이드 포스포네이트유도체, 그의 염 및 합성 방법 Expired - Fee Related KR100441638B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020010003087 2001-01-19
KR20010003087 2001-01-19

Publications (2)

Publication Number Publication Date
KR20020062216A KR20020062216A (ko) 2002-07-25
KR100441638B1 true KR100441638B1 (ko) 2004-07-23

Family

ID=36241797

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2002-0003051A Expired - Fee Related KR100441638B1 (ko) 2001-01-19 2002-01-18 새로운 에이사이클릭 뉴클레오사이드 포스포네이트유도체, 그의 염 및 합성 방법

Country Status (22)

Country Link
US (3) US7157448B2 (https=)
EP (1) EP1358198B1 (https=)
JP (1) JP3959348B2 (https=)
KR (1) KR100441638B1 (https=)
CN (1) CN100347185C (https=)
AR (1) AR035933A1 (https=)
AT (1) ATE478887T1 (https=)
AU (1) AU2002230230B2 (https=)
BR (1) BR0206165A (https=)
CA (1) CA2433591C (https=)
DE (1) DE60237429D1 (https=)
DK (1) DK1358198T3 (https=)
EG (1) EG24382A (https=)
ES (1) ES2350197T3 (https=)
MX (1) MXPA03006001A (https=)
MY (1) MY141789A (https=)
NZ (1) NZ526632A (https=)
PL (1) PL212730B1 (https=)
PT (1) PT1358198E (https=)
RU (1) RU2266294C2 (https=)
WO (1) WO2002057288A1 (https=)
ZA (1) ZA200304181B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100935904B1 (ko) 2007-01-17 2010-01-07 주식회사 엘지생명과학 항바이러스성 약물의 말레산 단일염 및 이를 함유하는약제학적 조성물
KR20180009195A (ko) 2016-07-18 2018-01-26 일동제약(주) 항바이러스성 약물의 오로트산염, 이의 제조 방법 및 상기 염을 포함하는 약제학적 조성물

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY141789A (en) 2001-01-19 2010-06-30 Lg Chem Investment Ltd Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.
AU2002252179A1 (en) * 2001-03-01 2002-09-19 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
US7241890B2 (en) 2001-10-30 2007-07-10 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
CA2499889A1 (en) * 2002-09-26 2004-04-08 Lg Life Sciences Ltd. (+)-trans-isomers of (1-phosphonomethoxy-2-alkylcyclopropyl) methyl nucleoside derivatives, process for the preparation of stereoisomers thereof, and use of antiviral agents thereof
KR20060070572A (ko) 2003-09-18 2006-06-23 콘포마 세러퓨틱스 코포레이션 Ｈｓｐ90-저해제로서의 신규 헤테로시클릭 화합물
KR20050062940A (ko) * 2003-12-19 2005-06-28 주식회사 엘지생명과학 디이소프로필((1-((2-아미노-6-할로-9ｈ-퓨린-9-일)메틸)사이클로프로필)옥시)-메틸포스포네이트의 새로운 제조방법
KR20050062944A (ko) * 2003-12-19 2005-06-28 주식회사 엘지생명과학 디이소프로필((1-((2-아미노-6-클로로-9ｈ-퓨린-9-일)메틸)사이클로프로필)옥시)-메틸포스포네이트의 새로운 제조방법
CN1921867B (zh) * 2004-02-17 2010-05-05 株式会社Lg生命科学 用于治疗hiv感染的膦酸核苷衍生物
KR101033290B1 (ko) * 2004-07-02 2011-05-09 주식회사 엘지생명과학 다이아이소프로필((1-(하이드록시메틸)-사이클로프로필)옥시)메틸포스포네이트의 새로운 제조 방법
WO2006066074A2 (en) 2004-12-16 2006-06-22 The Regents Of The University Of California Lung-targeted drugs
CA2602257A1 (en) 2005-03-30 2006-10-05 Conforma Therapeutics Corporation Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors
CA2641832C (en) * 2006-02-27 2012-10-23 Illumination Management Solutions Inc. An improved led device for wide beam generation
US8434912B2 (en) * 2006-02-27 2013-05-07 Illumination Management Solutions, Inc. LED device for wide beam generation
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
EP2420238A3 (en) 2007-04-13 2012-03-07 Southern Research Institute Anti-angiogenic agents
WO2008144672A1 (en) * 2007-05-21 2008-11-27 Illumination Management Solutions, Inc. An improved led device for wide beam generation and method of making the same
EP2326870B1 (en) * 2008-08-14 2017-01-25 Cooper Technologies Company Led devices for offset wide beam generation
US8256919B2 (en) * 2008-12-03 2012-09-04 Illumination Management Solutions, Inc. LED replacement lamp and a method of replacing preexisting luminaires with LED lighting assemblies
CN102093422B (zh) 2009-12-10 2015-02-25 中国人民解放军军事医学科学院毒物药物研究所 无环核苷膦酸酯衍生物及其医药用途
CN102286026B (zh) * 2010-06-18 2014-07-02 中国人民解放军军事医学科学院毒物药物研究所 无环核苷酸类似物的盐及其晶型和药物组合物
RU2606845C2 (ru) 2010-12-10 2017-01-10 СИГМАФАРМ ЛЭБОРЭТОРИЗ, ЭлЭлСи Высокостабильные композиции перорально активных аналогов нуклеотидов или перорально активных пролекарств аналогов нуклеотидов
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
EA201892769A3 (ru) 2013-03-15 2019-08-30 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Сложные диэфиры ациклических нуклеозидфосфонатов
CN104119385B (zh) * 2014-07-24 2017-04-05 廖国超 核苷类似物的磷酸酯前药及其应用
BR112017005111B1 (pt) 2014-09-15 2023-02-14 The Regents Of The University Of California Compostos análogos de nucleotídeo acíclico, composição farmacêutica contendo tais compostos, e usos da composição no tratamento de uma infecção por papilomavírus
CN106432330B (zh) * 2015-08-11 2019-02-01 天津科伦药物研究有限公司 Lb80380药物的中间体化合物及其制备方法和用途
WO2017048956A1 (en) 2015-09-15 2017-03-23 The Regents Of The University Of California Nucleotide analogs
CN107849074A (zh) * 2016-01-19 2018-03-27 四川海思科制药有限公司 一种核苷类似物的烷氧烷基酯前药及其应用
CN106977548A (zh) * 2016-01-19 2017-07-25 四川海思科制药有限公司 倍司福韦复合物及其制备方法和用途
CN108276443A (zh) * 2017-01-06 2018-07-13 米文君 一种新的化合物及其用途
KR102096144B1 (ko) * 2017-07-03 2020-04-01 주식회사 엘지화학 포스포네이트 뉴클레오사이드계 b형 간염 치료제 합성용 중간체 화합물의 연속식 제조방법
CN108997429B (zh) * 2018-07-27 2020-10-30 广州粤美医药科技有限公司 一种制备贝西福韦的方法
CN113735863A (zh) * 2021-09-29 2021-12-03 武汉九州钰民医药科技有限公司 Wee1抑制剂adavosertib的制备工艺
CN113880883A (zh) * 2021-11-11 2022-01-04 奥锐特药业股份有限公司 核苷类磷酸酯前药的制备方法
CN114560463B (zh) * 2022-03-23 2023-10-20 福州大学 一种核壳结构的氮掺杂碳壳包裹碳化钼核微米球材料的制备方法
IL318465A (en) 2022-07-21 2025-03-01 Antiva Biosciences Inc Compositions and dosage forms for the treatment of HPV infection and HPV-induced neoplasia

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04253989A (ja) * 1990-07-04 1992-09-09 Merrell Dow Pharmaceut Inc ９−プリニルホスホン酸誘導体
US5302585A (en) * 1990-04-20 1994-04-12 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
US5449840A (en) * 1991-03-05 1995-09-12 Ajinomoto Co., Inc. Cyclopropane derivative
US5874577A (en) * 1996-04-03 1999-02-23 Medichem Research, Inc. Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof
US5977089A (en) * 1996-07-26 1999-11-02 Gilead Sciences, Inc. Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1494321A (en) * 1974-08-08 1977-12-07 Ici Ltd Prostanoic acid derivatives
US5688778A (en) * 1989-05-15 1997-11-18 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
GB8922076D0 (en) * 1989-09-28 1989-11-15 Beecham Group Plc Novel process
US5177104A (en) 1990-04-03 1993-01-05 E. R. Squibb & Sons, Inc. 6-α-hydroxy derivatives of mevinic acids
EP0481214B1 (en) * 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US5817647A (en) * 1993-04-01 1998-10-06 Merrell Pharmaceuticals Inc. Unsaturated acetylene phosphonate derivatives of purines
ATE199906T1 (de) * 1993-06-29 2001-04-15 Mitsubishi Chem Corp Phosphonat-nukleotid ester-derivate
EP0719274A1 (en) * 1993-09-17 1996-07-03 Gilead Sciences, Inc. Method for dosing therapeutic compounds
WO1995022330A1 (en) 1994-02-17 1995-08-24 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
IT1270008B (it) 1994-09-23 1997-04-16 Ist Superiore Sanita Derivati purinici ed 8-azapurinici atti al trattamento terapeutico dell'aids
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
US5877166A (en) * 1996-04-29 1999-03-02 Sri International Enantiomerically pure 2-aminopurine phosphonate nucleotide analogs as antiviral agents
US5935946A (en) * 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
EP0988304B1 (en) 1997-08-15 2001-05-02 Medivir Ab Nucleosides analogues, such as antivirals including inhibitors of retroviral reverse transcriptase and the dna polymerase of hepatitis b virus (hbv)
MY141789A (en) * 2001-01-19 2010-06-30 Lg Chem Investment Ltd Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.
EP1490015B1 (en) * 2002-03-15 2009-09-23 Wayne State University Novel 2-amino-9-((2-hydroxymethyl) cyclopropylidenemethyl) purines as antiviral agents
CA2499889A1 (en) * 2002-09-26 2004-04-08 Lg Life Sciences Ltd. (+)-trans-isomers of (1-phosphonomethoxy-2-alkylcyclopropyl) methyl nucleoside derivatives, process for the preparation of stereoisomers thereof, and use of antiviral agents thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302585A (en) * 1990-04-20 1994-04-12 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
JPH04253989A (ja) * 1990-07-04 1992-09-09 Merrell Dow Pharmaceut Inc ９−プリニルホスホン酸誘導体
US5449840A (en) * 1991-03-05 1995-09-12 Ajinomoto Co., Inc. Cyclopropane derivative
US5874577A (en) * 1996-04-03 1999-02-23 Medichem Research, Inc. Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof
US5977089A (en) * 1996-07-26 1999-11-02 Gilead Sciences, Inc. Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100935904B1 (ko) 2007-01-17 2010-01-07 주식회사 엘지생명과학 항바이러스성 약물의 말레산 단일염 및 이를 함유하는약제학적 조성물
KR20180009195A (ko) 2016-07-18 2018-01-26 일동제약(주) 항바이러스성 약물의 오로트산염, 이의 제조 방법 및 상기 염을 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
CN100347185C (zh) 2007-11-07
ZA200304181B (en) 2004-10-06
US7605147B2 (en) 2009-10-20
ES2350197T3 (es) 2011-01-20
AU2002230230B2 (en) 2005-05-26
CA2433591A1 (en) 2002-07-25
JP2004518675A (ja) 2004-06-24
US20060293284A1 (en) 2006-12-28
US20040063668A1 (en) 2004-04-01
US7157448B2 (en) 2007-01-02
RU2003125372A (ru) 2005-01-20
US7723319B2 (en) 2010-05-25
EP1358198A4 (en) 2008-03-05
EP1358198B1 (en) 2010-08-25
AR035933A1 (es) 2004-07-28
PL212730B1 (pl) 2012-11-30
US20100004440A1 (en) 2010-01-07
WO2002057288A1 (en) 2002-07-25
KR20020062216A (ko) 2002-07-25
CN1487949A (zh) 2004-04-07
JP3959348B2 (ja) 2007-08-15
MXPA03006001A (es) 2003-09-10
PL373670A1 (en) 2005-09-05
HK1062017A1 (en) 2004-10-15
PT1358198E (pt) 2010-10-01
ATE478887T1 (de) 2010-09-15
EP1358198A1 (en) 2003-11-05
CA2433591C (en) 2009-07-28
BR0206165A (pt) 2004-02-03
DK1358198T3 (da) 2010-10-04
DE60237429D1 (de) 2010-10-07
MY141789A (en) 2010-06-30
NZ526632A (en) 2005-10-28
EG24382A (en) 2009-04-05
RU2266294C2 (ru) 2005-12-20

Similar Documents

Publication Publication Date Title
KR100441638B1 (ko) 새로운 에이사이클릭 뉴클레오사이드 포스포네이트유도체, 그의 염 및 합성 방법
EP0632048B1 (en) Phosphonate-nucleotide ester derivatives
AU2002230230A1 (en) Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same
CA2623522C (en) Modified 4'-nucleosides as antiviral agents
JP3421335B2 (ja) 鏡像異性的に純粋なβ−Ｄ−（−）−ジオキソラン−ヌクレオシド
JP3519736B2 (ja) エナンチオマー的に純粋なβ‐Ｄ‐ジオキソラン−ヌクレオシド
US6767900B2 (en) Phosphonate nucleotide compound
TW470748B (en) Nucleotide analogs
KR950006713B1 (ko) 6-치환 비환식 피리미딘뉴클레오시드 유도체 및 그 유도체를 유효성분으로 하는 항 비루스제
WO1997000262A1 (fr) Nucleotides derives de phosphonates
KR20040027452A (ko) (1-포스포노메톡시-2-알킬사이클로프로필)메틸뉴클레오사이드유도체의 (+)-트랜스 이성질체, 그의 입체이성질체의제조방법 및 항바이러스제로서의 용도
CN1921867B (zh) 用于治疗hiv感染的膦酸核苷衍生物
AU3760793A (en) Antiviral phosphonic acid derivatives of purine analogues
JPH06501253A (ja) ヘテロ環状化合物
JP2006524672A (ja) ウイルス感染の治療において使用するための複素環式化合物
JP3580377B2 (ja) ホスホナートヌクレオチドエステル誘導体
KR20070018868A (ko) Ｈｉｖ 감염 치료에 유용한 뉴클레오사이드 포스포네이트유도체
HK1062017B (en) Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same
JPWO2001064693A1 (ja) ホスホナートヌクレオチド化合物

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

St.27 status event code: A-3-3-R10-R13-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

St.27 status event code: A-3-3-R10-R13-asn-PN2301

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U11-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 7

St.27 status event code: A-4-4-U10-U11-oth-PR1001

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

Fee payment year number: 8

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 9

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20130612

Year of fee payment: 10

PR1001 Payment of annual fee

Fee payment year number: 10

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20140630

Year of fee payment: 11

PR1001 Payment of annual fee

Fee payment year number: 11

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20150618

Year of fee payment: 12

PR1001 Payment of annual fee

Fee payment year number: 12

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20160607

Year of fee payment: 13

PR1001 Payment of annual fee

Fee payment year number: 13

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

S17-X000 Non-exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S17-lic-X000

FPAY Annual fee payment

Payment date: 20170628

Year of fee payment: 14

PR1001 Payment of annual fee

Fee payment year number: 14

St.27 status event code: A-4-4-U10-U11-oth-PR1001

A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

Protection beyond ip right term event data comment text: Claim Total Quantity : 6, Claim Number : 1,3,4,5,6,8, Period Limitation Text : 1825, Comment Text : 31 5189

St.27 status event code: A-4-4-G10-G18-tex-PA0101

PE0702 Decision to register extension of term of patent right by permit, etc.

Protection beyond ip right term event data comment text: Claim Total Quantity : 6, Claim Number : 1,3,4,5,6,8, Period Limitation Text : 1825, Comment Text : 31 5189

St.27 status event code: A-4-4-G10-G20-tex-PE0702

FPAY Annual fee payment

Payment date: 20180619

Year of fee payment: 15

PR1001 Payment of annual fee

Fee payment year number: 15

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20190625

Year of fee payment: 16

PR1001 Payment of annual fee

Fee payment year number: 16

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 17

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 18

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PC1903 Unpaid annual fee

Not in force date: 20220715

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220715

St.27 status event code: N-4-6-H10-H13-oth-PC1903

K11-X000 Ip right revival requested

St.27 status event code: A-6-4-K10-K11-oth-X000

K12-X000 Request for ip right revival rejected

St.27 status event code: A-6-4-K10-K12-oth-X000